Dynamics of bone turnover in children with GH deficiency treated with GH until final height

Endocrine Unit, Division of Pediatrics, Department of Reproductive Medicine and Pediatrics, University of Pisa, Pisa, Italy.

OBJECTIVE: To examine the dynamics of bone turnover in children with growth hormone deficiency (GHD) during long-term treatment. DESIGN: We longitudinally measured growth velocity and serum concentrations of osteocalcin (OC), carboxyterminal propeptide of type I procollagen (PICP), and cross-linked carboxyterminal telopeptide of type I collagen (ICTP) in 24 patients with GHD during long-term GH treatment until final height (age: 7.7+/-0.7 and 16.9+/-0.5 years at baseline and at final height respectively). RESULTS: At baseline, OC, PICP, and ICTP levels were significantly (P<0.0001) reduced in comparison with prepubertal bone age-matched controls (10.2+/-2.3 microgram/l and 22.5+/-7.6 microgram/l; 187.8+/-26.2 microgram/l and 328. 4+/-74.3 microgram/l; 7.7+/-2.0 microgram/l and 14.2+/-1.3 microgram/l respectively). During the first year of treatment mean levels of the bone markers increased significantly (P<0.0001) with a peak at 12 months. After the first year of treatment, OC and PICP levels progressively declined, whereas ICTP levels remained stable until the final height; in any case, bone marker levels remained significantly higher (P<0.03-P<0.0001) than baseline. The change in bone marker levels at 6 and 12 months of treatment with respect to the baseline values was not related to growth rate during long-term treatment or final height. CONCLUSIONS: The results show that children with GHD have reduced bone turnover at baseline, and that long-term GH treatment is associated with a stimulation of bone turnover. OC, PICP, and ICTP do not predict growth rate during long-term treatment or final height in children with GHD.

This article has been cited by other articles:

				V. Tangpricha, M. Luo, C. Fernandez-Estivariz, L. H. Gu, N. Bazargan, J.-M. Klapproth, S. V. Sitaraman, J. R. Galloway, L. M. Leader, and T. R. Ziegler Growth Hormone Favorably Affects Bone Turnover and Bone Mineral Density in Patients With Short Bowel Syndrome Undergoing Intestinal Rehabilitation JPEN J Parenter Enteral Nutr, November 1, 2006; 30(6): 480 - 486. [Abstract] [Full Text] [PDF]

				P. Koutkia, B. Canavan, J. Breu, and S. Grinspoon Effects of Growth Hormone-Releasing Hormone on Bone Turnover in Human Immunodeficiency Virus-Infected Men with Fat Accumulation J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2154 - 2160. [Abstract] [Full Text] [PDF]

				G. I. Baroncelli, S. Bertelloni, L. Galli, F. Sodini, and G. Saggese Cortical Bone Density Is Normal in Prepubertal Children with Growth Hormone (GH) Deficiency, but Initially Decreases during GH Replacement due to Early Bone Remodeling J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2505 - 2506. [Full Text] [PDF]

				R. Schweizer, D. D. Martin, C. P. Schwarze, G. Binder, A. Georgiadou, J. Ihle, and M. B. Ranke Cortical Bone Density Is Normal in Prepubertal Children with Growth Hormone (GH) Deficiency, but Initially Decreases during GH Replacement due to Early Bone Remodeling J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5266 - 5272. [Abstract] [Full Text] [PDF]

				S. M. Shalet, E. Shavrikova, M. Cromer, C. J. Child, E. Keller, J. Zapletalova, T. Moshang, W. F. Blum, J. J. Chipman, C. A. Quigley, et al. Effect of Growth Hormone (GH) Treatment on Bone in Postpubertal GH-Deficient Patients: A 2-Year Randomized, Controlled, Dose-Ranging Study J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4124 - 4129. [Abstract] [Full Text] [PDF]

				G. I. Baroncelli, S. Bertelloni, F. Sodini, and G. Saggese Lumbar Bone Mineral Density at Final Height and Prevalence of Fractures in Treated Children with GH Deficiency J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3624 - 3631. [Abstract] [Full Text] [PDF]